Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- N/A
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Sacituzumab Govitecan In TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- Status
- TERMINATED
- Phase
- PHASE1
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- N/A
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Sitravatinib in Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
- Status
- COMPLETED
- Phase
- NA
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
- Status
- UNKNOWN
- Phase
- PHASE1
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2